Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Avalo Therapeutics
Avalo Announces Participation in September Investor Conferences
September 04, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
July 16, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 09, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
June 24, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
TRML
Avalo Reports 2023 Financial Results and Provides Business Updates
March 29, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
SLRN
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
December 27, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
December 07, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
September 26, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
HRZN
Avalo Enters into Agreement to Divest AVTX-800 Series
September 12, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo to Participate in SVB Securities Therapeutics Forum
July 06, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
June 26, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 22, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo to Present at ATS 2023 Respiratory Innovation Summit
May 15, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Reports 2022 Financial Results and Provides Business Updates
March 29, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
March 07, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
February 02, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
February 02, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
January 17, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 07, 2022
From
Avalo Therapeutics
Via
GlobeNewswire
Tickers
AVTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright